Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

The following is a summary of “Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study,” published in the January 2025 issue ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

When sick, it will be best to stay home, isolate and stay away from others. The US CDC recommends the RSV vaccine for all adults aged 75 and older, as well as for adults aged 60 to 74 who are at ...

Marc Watkins, M.D., chief medical officer at Kroger Health, discusses RSV and how people can protect themselves and their ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...